| Customization: | Available |
|---|---|
| Powder: | Yes |
| Customized: | Customized |
|
Still deciding? Get samples of $ !
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
| Product Name | Sunitinib |
| CAS | 557795-19-4 |
| Appearance | White crystalline powder |
| MF | C22H27FN4O2 |
| MW | 402.49800 |
| Purity | 99% |
| Shelf Life | 2 Years |
Sunitinib is a cancer medicine that interferes with the growth and spread of cancer cells in the body. Sunitinib is used to treat certain types of advanced or progressive tumors of the digestive system, the pancreas, or the kidneys.Sunitinib may also be used for purposes not listed in this medication guide.
Sunitinib is an inhibitor of multiple receptor tyrosine kinases (RTKs) involved in tumor proliferation and angiogenesis, including platelet-derived receptors (PDGFR), vascular endothelial receptors (VEGFR), and stem cell factor receptor (KIT). It was launched as an oral treatment for gastrointestinal stromal tumors (GIST) and advanced renal-cell carcinoma (RCC). In vitro, sunitib inhibits VEGFR2, PDGFRα, PDGFRβ, KIT, and FLT3 receptors with IC50 values in the 4-14nM range, and the ligand-dependent autophosphorylation of VEGFR2 and PDGFRb with IC50s of approximately 10 nM.
It inhibits the growth of tumor cells expressing dysregulated target RTKs in vitro and inhibits PDGFRb- and VEGFR2-dependent tumor angiogenesis in vivo. Sunitinib exhibits broad and potent antitumor activity, causing regression in murine models of human epidermal (A431), colon (Colo205 and HT-29), lung (NCI-H226 and H460), breast (MDA-MB-435), prostate (PC3-3M-luc), and renal (786-O) cancers, and suppressing or delaying the growth of many others, including the C6 rat and SF763 T human glioma xenografts and B16 melanoma lung cancer.
){kind=link}